TERAPET expands into South Korea through strategic partnership with MediinHealthcare

Geneva, Switzerland – 9 February 2026 

TERAPET SA has entered into a new strategic partnership with MediinHealthcare Co., Ltd., an established provider of advanced medical technologies with strong expertise in radiation oncology and particle therapy in South Korea.

Under this agreement, MediinHealthcare will serve as TERAPET’s official distributor in South Korea, supporting clinical sites through local commercial activities and customer engagement, and facilitating the adoption of our flagship platform, Qualyscan®, across leading particle therapy centers.

This collaboration represents a key step in TERAPET’s expansion across Asia and strengthens its ability to support customers through dedicated local teams. Qualyscan® enables end-to-end verification of particle beam delivery by combining advanced PET detector technology, radiation-tolerant electronics, and dedicated reconstruction software, providing clinical teams with clear, actionable insights to optimize QA routines and reinforce confidence in treatment delivery.

South Korea is a rapidly advancing market in radiation oncology and particle therapy, with centers of excellence actively adopting innovative technologies to enhance clinical performance and workflow efficiency. Through MediinHealthcare’s strong national presence and deep understanding of the clinical ecosystem, TERAPET aims to accelerate access to Qualyscan® and support the integration of imaging-driven verification into routine clinical practice.

Christina Vallgren, CEO of TERAPET SA, said:

“South Korea is a particularly important market for TERAPET, as our second clinical installation was carried out at Yonsei Cancer Center in Seoul. MediinHealthcare brings the local expertise and clinical reach needed to further scale advanced verification technologies across the country. This partnership allows us to work closely with leading centers to integrate Qualyscan® into daily clinical workflows and support the next generation of imaging-driven quality assurance.”

YoungJun Kim, Regional Business Director at MediinHealthcare Co., Ltd., said:

“Partnering with TERAPET allows us to bring advanced PET-based verification solutions to the South Korean market. We believe Qualyscan® can deliver meaningful clinical value by strengthening workflow efficiency and treatment verification. MediinHealthcare is fully committed to supporting customers locally and ensuring a successful adoption across leading particle therapy centers.”

About MediinHealthcare Co., Ltd.

MediinHealthcare Co., Ltd. is a South Korea–based provider of advanced medical technologies with strong expertise in radiation oncology and particle therapy, supporting leading hospitals and clinical centers nationwide. Focused on innovation, clinical value, and customer service, the company partners with global MedTech leaders to introduce high-impact solutions and ensure their successful adoption through strong local expertise.